Guiyang Xintian Pharmaceutical Co.,Ltd. Stock

Equities

002873

CNE100002QB5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
12.02 CNY -1.88% Intraday chart for Guiyang Xintian Pharmaceutical Co.,Ltd. +0.92% -3.53%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 1.06B 147M Sales 2025 * 1.19B 165M Capitalization 2.77B 383M
Net income 2024 * 101M 13.98M Net income 2025 * 116M 16.06M EV / Sales 2024 * 2.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.32 x
P/E ratio 2024 *
27.3 x
P/E ratio 2025 *
24 x
Employees 1,958
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.42%
More Fundamentals * Assessed data
Dynamic Chart
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces Profit Distribution Proposal for 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. signed Transaction Framework Agreement to acquire remaining 85.12% stake in Shanghai Huilun Biotechnology Co., Ltd. CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback announced on December 23, 2023 has closed with 4,017,200 shares, representing 1.73% for CNY 38.41 million. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback. CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 15 million worth of its shares. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
More news
1 day-1.88%
1 week+0.92%
Current month+0.92%
1 month-6.02%
3 months+32.67%
6 months-3.38%
Current year-3.53%
More quotes
1 week
11.79
Extreme 11.79
12.30
1 month
10.39
Extreme 10.39
12.81
Current year
7.59
Extreme 7.59
14.33
1 year
7.59
Extreme 7.59
15.24
3 years
7.59
Extreme 7.59
20.12
5 years
7.02
Extreme 7.0204
20.12
10 years
6.63
Extreme 6.6297
20.12
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 95-08-10
Director of Finance/CFO 51 18-01-31
Director/Board Member 47 21-03-31
Members of the board TitleAgeSince
Chief Executive Officer 60 95-08-10
Director/Board Member 57 95-08-10
Corporate Officer/Principal 55 06-03-31
More insiders
Date Price Change Volume
24-05-10 12.02 -1.88% 1,946,719
24-05-09 12.25 +0.66% 2,184,963
24-05-08 12.17 -0.25% 2,118,886
24-05-07 12.2 +0.16% 2,538,679

End-of-day quote Shenzhen S.E., May 09, 2024

More quotes
Guiyang Xintian Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sales of Chinese patent drugs. The Company manufactures its products in the forms of capsules, mixture, granules, syrup, gel and tablets. The Company’s main products include Ningmitai Capsule, Kuntai Capsule, Kushen Gel and Xiaokucao Oral Liquid .The Company distributes its products in the domestic market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
12.02
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002873 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW